In vivo evaluation of a novel dexamethasone-heparin-double-coated stent for inhibition of artery restenosis and thrombosis

Journal of Materials Science: Materials in Medicine

Volumn 22, Issue 6, 2011, Pages 1615-1623

  Guo, Qing Kui ^a   Lu, Zhi Qian ^a   Wang, Jin Ye ^b   Li, Tao ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AREA REDUCTION; FEMORAL ARTERY; FOUR-GROUP; HISTOLOGICAL SECTION; ILIAC ARTERIES; IN-VIVO; LUMEN REDUCTION; MINIPIGS; NEOINTIMAL HYPERPLASIA; PORCINE MODELS; RESTENOSIS; SHORT TERM; SPRAY-DRYING METHOD;

DISEASES; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING;

POLYSACCHARIDES;

DEXAMETHASONE; HEPARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTOGRAPHY; ARTERY INTIMA PROLIFERATION; ARTERY OCCLUSION; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; FEMORAL ARTERY; HISTOLOGY; ILIAC ARTERY; IMPLANTATION; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; STENT; SWINE; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICOAGULANTS; BLOOD VESSEL PROSTHESIS; COATED MATERIALS, BIOCOMPATIBLE; DEXAMETHASONE; DRUG-ELUTING STENTS; GRAFT OCCLUSION, VASCULAR; HEPARIN; MALE; MATERIALS TESTING; MICROSPHERES; MODELS, BIOLOGICAL; SWINE; THROMBOSIS;

SUIDAE; SUS;

EID: 80051590835     PISSN: 09574530     EISSN: 15734838     Source Type: Journal    
DOI: 10.1007/s10856-011-4334-3     Document Type: Article

References (43)

1. Sims EC, Rothman MT, Warner TD, et al. Coronary artery brachytherapy. Clin Oncol (R Coil Radiol). 2002;14:313-26. (Pubitemid 34919262)
2. Martinez-Elbal L, Ruiz-Nodar JM, Zueco J, et al. Direct coronary stenting versus stenting with balloon pre-dilation: immediate and follow-up results of a multicentre, prospective, randomized study. The DISCO trial. Eur Heart J. 2002;23:633-40. (Pubitemid 35204248)
3. Kukreja N, Serruys PW, De Bruyne B, et al. Sirolimus-eluting stents, bare metal stents or coronary artery bypass grafting for patients with multivessel disease including involvement of the proximal left anterior descending artery: analysis of the Arterial Revascularization Therapies study part 2 (ARTS-II). Heart. 2009;95:1061-6.
4. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998-1008. (Pubitemid 46376800)
5. Matsumoto K, Morishita R, Moriguchi A, et al. Inhibition of neointima by angiotensin-converting enzyme inhibitor in porcine coronary artery balloon-injury model. Hypertension. 2001;37:270-4. (Pubitemid 32199087)
6. Hayashi K, Nakamura S, Morishita R, et al. In vivo transfer of human hepatocyte growth factor gene accelerates re-endothelialization and inhibits neointimal formation after balloon injury in rat model. Gene Ther. 2000;7:1664-71.
7. Kazuhiro Y, Ken-ichi I, Katsuaki T, et al. Suppression of acute and chronic rejection by hepatocyte growth factor in a murine model of cardiac transplantation. Circulation. 2004;110:1650-7.
8. Dong J, Sun QS, Wang JY. Basic study of corn protein, zein, as a biomaterial in tissue engineering, surface morphology and biocompatibility. Biomaterials. 2004;25:4691-7. (Pubitemid 38561156)
9. Sun QS, Dong J, Lin ZX, et al. Comparison of cytocompatibility of zein film with other biomaterials and its degradability in vitro. Biopolymers. 2005;78:268-74. (Pubitemid 41191966)
10. Liu XM, Sun QS, Wang HJ, et al. Microspheres of corn protein, zein, for an ivermectin drug delivery system. Biomaterials. 2005;26:109-15.
11. Gong SJ, Wang HJ, Sun QS, et al. Mechanical properties and in vitro biocompatibility of porous zein scaffolds. Biomaterials. 2006;27:3793-9.
12. Di Ling, Liu W, Liu Y et al. Effect of asymmetric distribution of phospholipids in ghost membrane from rat blood on peroxidation induced by ferrous ion. FEBS Lett., 2006, 80:685-690. (Pubitemid 43089706)
13. Wang JY, Wang LP, Ren QS. Atomic force microscope observation on biomembrane before and after peroxidation. Biophys Chem. 2007;131:105-10.
14. Liu W, Wang HJ, Wang LP, et al. Formation of high-molecularweight protein adducts by methyl docosahexaenoate peroxidation products. Biochim Biophys Acta. 2007;1774:258-66. (Pubitemid 46205486)
15. Wang HJ, Gong SJ, Lin ZX, et al. In vivo biocompatibility and mechanical properties of porous zein scaffolds. Biomaterials. 2007;28:3952-64.
16. Wang HJ, Fu JX, Wang JY. Effect of water vapor on the surface characteristics and cell compatibility of zein films. Colloids Surf B Biointerfaces. 2009;69:109-15.
17. Garcia-Touchard A, Burke SE, Toner JL, et al. Zotarolimuseluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks. Eur Heart J. 2006;27:988-93.
18. Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 1992;19:267-74.
19. Cilingiroglu M, Elliott J, Patel D, et al. Long-term effects of novel biolimus eluting DEVAX AXXESS plus nitinol selfexpanding stent in a porcine coronary model. Catheter Cardiovasc Interv. 2006;68:271-9. (Pubitemid 44167682)
20. Carter AJ, Aggarwal M, Kopia GA, et al. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res. 2004;63:617-24. (Pubitemid 39078675)
21. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202. (Pubitemid 43929240)
22. Nebeker JR, Virmani R, Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol. 2006;47:175-81. (Pubitemid 43005183)
23. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J. 2006;27:2784-814. (Pubitemid 44871464)
24. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009-19. (Pubitemid 46376801)
25. Lucas RA, Korol R, Pepine CJ. Inflammation in atherosclerosis. Some thoughts about acute coronary syndromes. Circulation. 2006;113:e728-32.
26. Fuster V, Moreno PR, Fayad ZA, et al. Atherothrombosis and high-risk plaque. Part I: evolving concepts. J Am Coll Cardiol. 2005;46:937-54. (Pubitemid 41316498)
27. Toutouzas K, Colombo A, Stefanadis C. Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J. 2004;25:1679-87. (Pubitemid 39286632)
28. Costa MA, Simon DI. Molecular basis of restenosis and drugeluting stents. Circulation. 2005;111:2257-73. (Pubitemid 40632443)
29. Gaspardone A, Versaci F. Coronary stenting and inflammation. Am J Cardiol. 2005;96(Suppl):65L-70L.
30. Dibra A, Mehili J, Braun S, et al. Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting. Am Heart J. 2005;150:344-50. (Pubitemid 41116262)
31. Liu X, De Scheerder I, Desmet W. Dexamethasone-eluting stent: an anti-inflammatory approach to inhibit coronary restenosis. Expert Rev Cardiovasc Ther. 2004;2:653-60. (Pubitemid 39255530)
32. Jimenez-Valero S, Santos B, Pajin F, et al. Clinical outcomes of dexamethasone-eluting stent implantation in ST-elevation acute myocardial infarction. Catheter Cardiovasc Interv. 2007;70:492-7. (Pubitemid 47597017)
33. König A, Leibig M, Rieber J, et al. Randomized comparison of dexamethasone-eluting stents with bare metal stent implantation in patients with acute coronary syndrome: serial angiographic and sonographic analysis. Am Heart J., 2007;153:979.e1-8.
34. Ribichini F, Tomai F, Paloscia L, et al. Steroid-eluting stents in patients with acute coronary syndrome: the Dexamethasone Eluting Stent Italian Registry. Heart. 2007;93:598-600. (Pubitemid 46707113)
35. Pesarini G, Ferrero V, Tomai F, et al. Steroid-eluting stents in patients with acute coronary syndromes. Angiographic results of DESIRE: Dexamethasone-Eluting Stent Italian REgistry. J Invasive Cardiol. 2009;21(3):86-91.
36. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic drug regimens after coronary artery stenting (STARS). N Engl J Med. 1998;339:1665-71. (Pubitemid 28550691)
37. Karrillon GJ, Morice MC, Benveniste E, et al. Intracoronary stent implantation with replacement of conventional anticoagulation by antiplatelet therapy. 30-day clinical outcome of the French Multicenter Registry. Circulation. 1996;94:1519-27. (Pubitemid 26320253)
38. Moussa I, Di Mario C, Reimers B, et al. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. J Am Coll Cardiol. 1997;29:6-12. (Pubitemid 27028713)
39. Orford JL, Lennon R, Melby S, et al. Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. J Am Coll Cardiol. 2002;40:1567-72. (Pubitemid 35253633)
40. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation. 2001;103:1967-71. (Pubitemid 32322224)
41. Mehran R, Aymong ED, Ashby DT, et al. Safety of an aspirinalone regimen after intracoronary stenting with a heparin-coated stent. Final results of the HOPE (HEPACOAT and an antithrombotic regimen of aspirin alone) Study. Circ., 2003;108:1078-83. (Pubitemid 37071517)
42. Lev EI, Assali AR, Teplisky I, et al. Comparison of outcomes up to six months of heparin-coated with noncoated stents after percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol. 2004;93:741-3. (Pubitemid 38338566)
43. Lee YK, Hyung Park J, Tae Moon H, et al. The short-term effects on restenosis and thrombosis of echinomycin-eluting stents topcoated with a hydrophobic heparin-containing polymer. Biomaterials. 2007;28:1523-30. (Pubitemid 46027247)